The US Centers for Disease Control and Prevention (CDC) has announced a significant change in its vaccine advisory policy, recommending that babies wait until they are two months old before receiving their first dose of the Hepatitis B vaccine. This decision has sent shockwaves through the medical community, with many experts expressing concerns about the potential impact on newborns.
The CDC's Advisory Committee on Immunization Practices (ACIP) voted 8-3 in favor of delaying the first dose of Hepatitis B to 24 days after birth, down from its current practice of administering it within 24 hours of birth. This change has been met with skepticism by some experts, who argue that it could lead to a significant increase in the number of newborns contracting Hepatitis B and developing chronic infections.
Dr. Scott Gottlieb, former commissioner of the Food and Drug Administration (FDA), warned that this decision is "a big unforced error" and will have serious consequences for public health. He pointed out that the CDC's policy change ignores the scientific consensus on the importance of administering Hepatitis B to newborns within 24 hours of birth.
Gottlieb also expressed concern about the potential impact of this policy change on other vaccine development, citing the example of the flu vaccine. The FDA has announced plans to eliminate immuno-bridging studies, which are used to demonstrate the effectiveness of new vaccines. This move is seen as a major setback for vaccine research and development.
Critics argue that the CDC's decision was influenced by external factors, including pressure from anti-vaccine groups. RFK Jr., a well-known skeptic of vaccines, has been accused of orchestrating the ACIP's decision to delay the Hepatitis B dose.
The consequences of this policy change are already being felt. Biotech stocks have plummeted following news of the CDC's decision, and many experts fear that it could lead to a decline in vaccine uptake among new mothers.
As the medical community continues to grapple with the implications of this policy change, one thing is clear: the decision will have far-reaching consequences for public health.
The CDC's Advisory Committee on Immunization Practices (ACIP) voted 8-3 in favor of delaying the first dose of Hepatitis B to 24 days after birth, down from its current practice of administering it within 24 hours of birth. This change has been met with skepticism by some experts, who argue that it could lead to a significant increase in the number of newborns contracting Hepatitis B and developing chronic infections.
Dr. Scott Gottlieb, former commissioner of the Food and Drug Administration (FDA), warned that this decision is "a big unforced error" and will have serious consequences for public health. He pointed out that the CDC's policy change ignores the scientific consensus on the importance of administering Hepatitis B to newborns within 24 hours of birth.
Gottlieb also expressed concern about the potential impact of this policy change on other vaccine development, citing the example of the flu vaccine. The FDA has announced plans to eliminate immuno-bridging studies, which are used to demonstrate the effectiveness of new vaccines. This move is seen as a major setback for vaccine research and development.
Critics argue that the CDC's decision was influenced by external factors, including pressure from anti-vaccine groups. RFK Jr., a well-known skeptic of vaccines, has been accused of orchestrating the ACIP's decision to delay the Hepatitis B dose.
The consequences of this policy change are already being felt. Biotech stocks have plummeted following news of the CDC's decision, and many experts fear that it could lead to a decline in vaccine uptake among new mothers.
As the medical community continues to grapple with the implications of this policy change, one thing is clear: the decision will have far-reaching consequences for public health.